2021-01-20T00:00:00.000+08:00
Ongoing

EA5163

EA5163
Cancer

EA5163-A Randomized, Phase III Study of Firstline Immunotherapy with or without Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC)

EA5163-A Randomized, Phase III Study of Firstline Immunotherapy with or without Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC)

Topic

EA5163

Description

S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

Contact

Florida

Peggy Mouradian

Florida Peggy Mouradian ::: (954) 370-7555